Eli Lillys Zepbound set to eclipse Wegovy in U.S. obesity drug market Eli Lillys new obesity drug poised to challenge ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Health authorities in Victoria, Australia's second-most populous state, on Tuesday issued a high-risk warning after ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly's blockbuster drugs ...

In a news release published Dec. 20, the FDA stated that Zepbound, part of the GLP-1 receptor agonist medicines that include Ozempic, was cleared to treat moderate to severe OSA in individuals ...

Shelby Knowles / Bloomberg / Getty Images Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker ...

which led him to enlist the aid of the injectable medication Zepbound, which the Food and Drug Administration approved last year to treat obesity. Like Mounjaro, Zepbound is a brand name for ...

Stocks are wavering in the early going on Wall Street at the start of a holiday-shortened week. The S&P 500 edged up 0.2% in ...

Eli Lilly and Company LLY announced that the FDA has approved its popular obesity drug, Zepbound (tirzepatide) for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.The medicine, part of the class known as GLP-1 ...